Phase II clinical trials of immunotherapy for MIBC
| Trial | Interventions | Agent description | Rate of downstaging at time of surgery | Rate of ypT0 at time of surgery |
| ABACUS (NCT02662309)41 | Atezolizumab | ICI | NR | 31% |
| PURE-01 (NCT02736266)151 | Pembrolizumab | ICI | 54% (to non-invasive disease) | 42% |
| NABUCCO (NCT03387761)152 | Nivolumab+ipilimumab | ICI | 58% (to non-invasive disease) | 45% |
| NCT02812420153 | Durvalumab+tremelimumab | ICI | 58% (to ypT1 or less) | 38% |
| BLASST-1 (NCT03294304)90 | Nivolumab+gemcitabine+cisplatin | ICI+chemotherapy | 66% | 34% |
| HCRN GU14-188 (NCT02365766)154 155 | Pembrolizumab+gemcitabine+cisplatin (eligible cohort) Pembrolizumab+gemcitabine (cisplatin-ineligible cohort) | ICI+chemotherapy | Cisplatin-eligible cohort I: 53% (to ypT0/Tis) Cisplatin-ineligible cohort II: 52% (to ypT0/Tis) | Cisplatin-eligible cohort I: 44% Cisplatin-ineligible cohort II: 45% |
| DUTRENEO (NCT03472274)91 | Durvalumab+tremelimumab | ICI | NR | 35% |
ICI, immune checkpoint inhibitor; MIBC, muscle-invasive bladder cancer; NR, not reported.